A phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies

Mitchell A. Garrison, Lisa A. Hammond, Charles E. Geyer, Garry Schwartz, Anthony W. Tolcher, Leslie Smetzer, Jose A. Figueroa, Murray Ducharme, John Coyle, Chris H. Takimoto, Robert L. De Jager, Eric K. Rowinsky